PDF herunterladen
Homeopathy 2019; 108(03): 150-157
DOI: 10.1055/s-0038-1676953
Homeopathy and Public Health
The Faculty of Homeopathy

Effect of Adjuvant Homeopathy with Usual Care in Management of Thrombocytopenia Due to Dengue: A Comparative Cohort Study

Debadatta Nayak
1   Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, Delhi, India
,
Vishal Chadha
2   Dr. Hedgewar Aarogya Sansthan, New Delhi, Delhi, India
,
Shruti Jain
1   Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, Delhi, India
,
Priyanka Nim
1   Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, Delhi, India
,
Jyoti Sachdeva
1   Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, Delhi, India
,
Garima Sachdeva
1   Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, Delhi, India
,
Kumar Vivekanand
1   Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, Delhi, India
,
Anil Khurana
1   Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, Delhi, India
,
Sunil M. Raheja
2   Dr. Hedgewar Aarogya Sansthan, New Delhi, Delhi, India
,
Raj K. Manchanda
1   Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, Delhi, India
› Institutsangaben Funding This study was funded by the Central Council for Research in Homoeopathy, New Delhi, India.
Weitere Informationen

Publikationsverlauf

22. Juli 2018

10. November 2018

Publikationsdatum:
05. März 2019 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background Dengue is an emerging threat to public health. At present, no clear modalities are available for the prevention and management of thrombocytopenia due to dengue. This article reports the clinical outcomes of integrative homeopathic care in a hospital setting during a severe outbreak of dengue in New Delhi, India, during the period September to December 2015.

Methods Based on preference, 138 patients received a homeopathic medicine along with usual care (H+UC), and 145 patients received usual care (UC) alone. Assessment of thrombocytopenia (platelet count < 100,000/mm3) was the main outcome measure. Kaplan–Meier analysis enabled comparison of the time taken to reach a platelet count of 100,000/mm3.

Results There was a statistically significantly greater rise in platelet count on day 1 of follow-up in the H+UC group compared with UC alone (mean difference = 12,337; 95% confidence interval [CI], 5,421 to 19,252; p = 0.001). This trend persisted until day 5 (mean difference = 14,809; 95% CI, 1,615 to 28,004; p = 0.02). The time taken to reach a platelet count of 100,000/mm3 was nearly 2 days earlier in the H+UC group compared with UC alone (H+UC: 3.44 days ± standard error of the mean [SEM] 0.18; 95% CI, 3.08 to 3.80; UC: 5.28 days ± SEM 0.29; 95% CI, 4.71 to 5.86; p < 0.001).

Conclusion These results suggest a positive role of adjuvant homeopathy in thrombocytopenia due to dengue. Randomized controlled trials may be conducted to obtain more insight into the comparative effectiveness of this integrative approach.

Keywords

dengue - thrombocytopenia - homeopathy - Crotalus horridus

Highlights

• One hundred and thirty-eight patients took homeopathy along with usual care (H+UC) and 145 patients were given usual care (UC) alone.


• Comparative analysis showed significantly greater rise in platelet count on day 1 of follow-up in the H+UC group compared with UC alone.


• The time taken to reach a platelet count of 100,000/mm3 was nearly 2 days earlier in the H+UC group compared with UC alone.


• These results suggest a positive role of adjuvant homeopathy in thrombocytopenia due to dengue.


 

  • References

  • 1 World Health Organization. Dengue guideline for diagnosis, treatment, prevention and control. Geneva: World Health Organization; 2009
    Suche in Google Scholar
  • 2 Vikram K, Nagpal BN, Pande V. , et al. An epidemiological study of dengue in Delhi, India. Acta Trop 2016; 153: 21-27
    CrossrefPubMedSuche in Google Scholar
  • 3 National Vector Borne Disease Control Program. Dengue. Govt. of India. Accessed January 9, 2019; Available at: http://nvbdcp.gov.in/index4.php?lang=1&level=0&linkid=431&lid=3715
    PubMed
  • 4 Shepard DS, Halasa YA, Tyagi BK. , et al; INCLEN Study Group. Economic and disease burden of dengue illness in India. Am J Trop Med Hyg 2014; 91: 1235-1242
    CrossrefPubMedSuche in Google Scholar
  • 5 Chaudhary R, Khetan D, Sinha S. , et al. Transfusion support to dengue patients in a hospital based blood transfusion service in north India. Transfus Apheresis Sci 2006; 35: 239-244
    CrossrefPubMedSuche in Google Scholar
  • 6 Lee MS, Hwang KP, Chen TC, Lu PL, Chen TP. Clinical characteristics of dengue and dengue hemorrhagic fever in a medical center of southern Taiwan during the 2002 epidemic. J Microbiol Immunol Infect 2006; 39: 121-129
    PubMedSuche in Google Scholar
  • 7 Sharma A, Charles K, Chadee D, Teelucksingh S. Dengue hemorrhagic fever in Trinidad and Tobago: a case for a conservative approach to platelet transfusion. Am J Trop Med Hyg 2012; 86: 531-535
    PubMedSuche in Google Scholar
  • 8 Lee TH, Wong JG, Leo YS. , et al. Potential harm of prophylactic platelet transfusion in adult dengue patients. PLoS Negl Trop Dis 2016; 10: e0004576
    CrossrefPubMedSuche in Google Scholar
  • 9 Lye DC, Archuleta S, Syed-Omar SF. , et al. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. Lancet 2017; 389: 1611-1618
    CrossrefPubMedSuche in Google Scholar
  • 10 Kurukularatne C, Dimatatac F, Teo DL, Lye DC, Leo YS. When less is more: can we abandon prophylactic platelet transfusion in Dengue fever?. Ann Acad Med Singapore 2011; 40: 539-545
    PubMedSuche in Google Scholar
  • 11 Whitehorn J, Rodriguez Roche R, Guzman MG. , et al. Prophylactic platelets in dengue: survey responses highlight lack of an evidence base. PLoS Negl Trop Dis 2012; 6: e1716
    CrossrefPubMedSuche in Google Scholar
  • 12 Jayanthi HK, Tulasi SK. Correlation study between platelet count, leukocyte count, nonhemorrhagic complications, and duration of hospital stay in dengue fever with thrombocytopenia. J Family Med Prim Care 2016; 5: 120-123
    CrossrefPubMedSuche in Google Scholar
  • 13 Chua MN, Molanida R, de Guzman M, Laberiza F. Prothrombin time and partial thromboplastin time as a predictor of bleeding in patients with dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 1993; 24: 141-143
    PubMedSuche in Google Scholar
  • 14 Chikkaveeraiah SK, Reddy R, Kumar A. A prospective observational study of dengue fever with thrombocytopenia with reference to treatment. Int J Res Med Sci. 2016; 4: 902-907
    PubMedSuche in Google Scholar
  • 15 Nedjadi T, El-Kafrawy S, Sohrab SS, Desprès P, Damanhouri G, Azhar E. Tackling dengue fever: current status and challenges. Virol J 2015; 12: 212
    CrossrefPubMedSuche in Google Scholar
  • 16 Cowperthwaite AC. Dengue. Textbook of the Practice of Medicine. Chicago: Halsey Bros. Co; 1904
    Suche in Google Scholar
  • 17 Murhy R. Homeopathic Medical Repertory. 1st Indian ed. New Delhi: IBPS; 1994
    Suche in Google Scholar
  • 18 Jacobs J, Fernandez EA, Merizalde B, Avila-Montes GA, Crothers D. The use of homeopathic combination remedy for dengue fever symptoms: a pilot RCT in Honduras. Homeopathy 2007; 96: 22-26
    Thieme ConnectPubMedSuche in Google Scholar
  • 19 Saeed-ul-Hassan S, Tariq I, Khalid A, Karim S. Comparative clinical study on the effectiveness of homeopathic combination remedy with standard maintenance therapy for dengue fever. Trop J Pharm Res 2013; 12: 767-770
    Suche in Google Scholar
  • 20 Mahesh S, Mahesh M, Vithoulkas G. Could homeopathy become an alternative therapy in dengue fever? An example of 10 case studies. J Med Life 2018; 11 (01) 75-82
    Suche in Google Scholar
  • 21 Government of India. Guidelines for clinical management of Dengue fever, dengue haemorrhagic fever and dengue shock syndrome. National Vector Borne Disease Control Program. 2008. Available at: http://www.nvbdcp.gov.in/Doc/Clinical%20Guidelines.pdf . Accessed April 19, 2018
    PubMed
  • 22 Noor NM, Al Bakri Abdullah MM, Yahaya AS, Ramli NA. Comparison of linear interpolation method and mean method to replace the missing values in environmental data set. Mater Sci Forum 2015; 803: 278-281
    PubMedSuche in Google Scholar
  • 23 Lee DK, In J, Lee S. Standard deviation and standard error of the mean. Korean J Anesthesiol 2015; 68: 220-223
    CrossrefPubMedSuche in Google Scholar
  • 24 Jayashree K, Manasa GC, Pallavi P, Manjunath GV. Evaluation of platelets as predictive parameters in dengue Fever. Indian J Hematol Blood Transfus 2011; 27: 127-130
    CrossrefPubMedSuche in Google Scholar
  • 25 Choudhury N. Blood transfusion in borderless South Asia. Asian J Transfus Sci 2011; 5: 117-120
    CrossrefPubMedSuche in Google Scholar
  • 26 Chaurasia R, Zaman S, Chatterjee K, Das B. Retrospective review of platelet transfusion practices during 2013 dengue epidemic of Delhi, India. Transfus Med Hemother 2015; 42: 227-231
    CrossrefPubMedSuche in Google Scholar
  • 27 Villar L, Dayan GH, Arredondo-García JL. , et al; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372: 113-123
    CrossrefPubMedSuche in Google Scholar
  • 28 Halstead SB, Aguiar M. Dengue vaccines: are they safe for travelers?. Travel Med Infect Dis 2016; 14: 378-383
    CrossrefPubMedSuche in Google Scholar
  • 29 Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 2016; 34: 1643-1647
    CrossrefPubMedSuche in Google Scholar
  • 30 Pallavi P, Ganesh CK, Jayashree K, Manjunath GV. Unfurling the rationale use of platelet transfusion in dengue Fever. Indian J Hematol Blood Transfus 2011; 27: 70-74
    CrossrefPubMedSuche in Google Scholar
  • 31 World Health Organization Country Office for India. National Vector Borne Disease Control Programme. National Guideline for Clinical Management of Dengue Fever. Government of India; 2014
    Suche in Google Scholar
  • 32 Garg P. Utility of clinical improvement and platelet count recovery time in counseling children hospitalized with suspected dengue in a resource poor setting. J Clin Diagn Res 2008; 2: 1149-1154
    PubMedSuche in Google Scholar
  • 33 Neidhard C. On the efficacy of Crotalus horridus in yellow fever; also in malignant, bilious, and remittent fevers: with an account of Humboldt's prophylactic inoculation of the venom of a serpent, at Havana, Cuba. New York, NY: William Radde; 1860
    Suche in Google Scholar
  • 34 Young PR, Ng LFP, Hall RA, Smith DW, Johansen CA. Arbovirus infections. In: Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ. , eds. Manson's Tropical Infectious Diseases. 23rd ed. London: W. B. Saunders; 2014: 129-161
    Suche in Google Scholar
  • 35 Chamnanchanunt S, Kanagaraj D, Thanachartwet V, Desakorn V, Rojnuckarin P. Early predictors of clinically significant bleeding in adults with dengue infection. Southeast Asian J Trop Med Public Health 2012; 43: 890-899
    PubMedSuche in Google Scholar
  • 36 King M, Nazareth I, Lampe F. , et al. Impact of participant and physician intervention preferences on randomized trials: a systematic review. JAMA 2005; 293: 1089-1099
    CrossrefPubMedSuche in Google Scholar